IMCF-106C is under clinical development by Immunocore and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II drugs for Endometrial Cancer have a 22% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IMCF-106C’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IMCF-106C is under development for the treatment of non-small cell lung cancer, synovial sarcoma, small cell lung cancer, ovarian cancer, endometrial cancer, urothelial carcinoma, triple-negative breast cancer , cutaneous melanoma, mucosal melanoma, head and neck squamous cell carcinoma, acute myeloid leukemia and uveal melanoma. It comprises of T cell receptor (TCR) with an anti-CD3 single-chain antibody fragment (scFv). The drug candidate is developed based on Immune mobilizing monoclonal T-cell receptor against cancer (ImmTAC) technology. It is administered through intravenous route. The drug candidate acts by targeting preferentially expressed antigen in melanoma (PRAME).
Immunocore is a biotechnology company. It focuses on the development of immunotherapeutic drugs for the treatment of cancer, infectious diseases, and autoimmune diseases. The company develops its drugs using proprietary T cell receptor (TCR) technology. Its products under development include IMC-C103C, IMC-F106C, IMC-I109V, IMC-M113V and IMCgp100. The company works in collaboration with various pharmaceutical companies, to develop its product candidates for the treatment of metastatic cutaneous melanoma; cancer; and other indications. It has presence in the UK, the US, Australia, New Zealand and Asia, Europe. Immunocore is headquartered in Oxfordshire, the UK.
For a complete picture of IMCF-106C’s drug-specific PTSR and LoA scores, buy the report here.